CSIMarket
 


Syros Pharmaceuticals Inc   (SYRS)
Other Ticker:  
 

Cumulative Syros Pharmaceuticals Inc 's Total Debt to Equity for Trailing Twelve Months Period

SYRS's Total Debt to Equity for Trailing Twelve Months Period and Total Debt, Equity growth


Select the Comparisons : Select the Ratio:

SYRS Total Debt to Equity for Trailing Twelve Months Period

(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
Y / Y Equity Growth 70.15 % 49.89 % 21.79 % -76.14 % -58.14 %
Y / Y Total Debt Growth 0.85 % 0.97 % 1.1 % 1.86 % 1.82 %
Total Debt to Equity for Trailing Twelve Months Period 0.41 0.46 0.53 0.57 0.42
Total Ranking # 1365 # 1743 # 656 # 1004 # 291
Seq. Equity Growth -16.43 % -1.11 % 316.43 % -50.56 % -26.37 %
Seq. Total Debt Growth 0.33 % 0.33 % -0.3 % 0.48 % 0.46 %


Total Debt to Equity for Trailing Twelve Months Period Comment for 12 Months ending at Mar 31 2023
On the trailing twelve months basis Despite net new borrowings of 0.33% Syros Pharmaceuticals Inc managed to decrease Total Debt to Equity for Trailing Twelve Months Period in I. Quarter to 0.41, above Syros Pharmaceuticals Inc 's average Total Debt to Equity for Trailing Twelve Months Period.
Total Debt to Equity for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies in Major Pharmaceutical Preparations industry 102 other companies have achieved lower Total Debt to Equity for Trailing Twelve Months Period than Syros Pharmaceuticals Inc . While total ranking remained unchanged compare to previous quarter at no. .

What is Debt to Equity Ratio?
SYRS Charts and Quotes
Total Debt to Equity SYRS in the most recent quarter
Total Debt to Equity for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 103
Sector # 249
S&P 500 # 1296


Total Debt to Equity for Trailing Twelve Months Period Statistics
High Average Low
0.46 0.1 0
(Dec 31 2022)   (Sep 30 2019)




Companies with similar average Total Debt to Equity for Trailing Twelve Months Period for 12 months ending Mar 31 2023, within Major Pharmaceutical Preparations Industry Total Debt to Equity for Trailing Twelve Months Period
Ocular Therapeutix Inc   1.12 
Adc Therapeutics Sa  1.10 
Ionis Pharmaceuticals Inc   1.10 
G1 Therapeutics Inc   1.09 
Acelrx Pharmaceuticals Inc  1.00 
Viatris Inc   0.99 
Pacira Biosciences inc   0.97 
Catalent Inc   0.92 
Innoviva Inc   0.92 
Ani Pharmaceuticals inc  0.91 
Prestige Consumer Healthcare Inc   0.91 
Entasis Therapeutics Holdings Inc   0.90 
Chembio Diagnostics Inc   0.88 
Fortress Biotech Inc   0.87 
Biovie Inc   0.83 
Elanco Animal Health Inc  0.81 
Perrigo Company Plc  0.81 
Tg Therapeutics inc   0.79 
Emergent Biosolutions Inc   0.79 
Avid Bioservices Inc   0.78 
Rockwell Medical inc   0.73 
Merck and Co Inc   0.72 
Journey Medical Corporation  0.72 
Royalty Pharma Plc  0.71 
Cryoport inc   0.71 
Ironwood Pharmaceuticals inc   0.71 
Arcutis Biotherapeutics Inc   0.68 
Durect Corp  0.68 
Maravai Lifesciences Holdings Inc   0.65 
Harmony Biosciences Holdings inc   0.59 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071